within Pharmacolibrary.Drugs.ATC.D;

model D07CB04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07CB04</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This is a combination topical medication containing dexamethasone, a potent corticosteroid with anti-inflammatory and immunosuppressive properties, and antibiotics (often combinations such as neomycin and gramicidin) used for the treatment of inflammatory skin conditions with suspected or confirmed bacterial infection. Such fixed combinations are approved and used primarily for dermatological conditions requiring both anti-inflammatory and antimicrobial effects.</p><h4>Pharmacokinetics</h4><p>No direct publication reports pharmacokinetic parameters for the fixed combination 'dexamethasone and antibiotics' (ATC D07CB04) in humans. The following parameters are estimated based on topical application of dexamethasone and absorption of related antibiotics through intact or inflamed skin, extrapolated from similar ointments.</p><h4>References</h4><ol><li><p>Bao, Z, et al., &amp; Wang, Y (2021). Glycol chitosan/oxidized hyaluronic acid hydrogel film for topical ocular delivery of dexamethasone and levofloxacin. <i>International journal of biological macromolecules</i> 167 659–666. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2020.11.214&quot;>10.1016/j.ijbiomac.2020.11.214</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33278439/&quot;>https://pubmed.ncbi.nlm.nih.gov/33278439</a></p></li><li><p>Gautam, M, et al., &amp; Sharma, B (2023). Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 39(2) 102–116. DOI:<a href=&quot;https://doi.org/10.1089/jop.2022.0144&quot;>10.1089/jop.2022.0144</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36757304/&quot;>https://pubmed.ncbi.nlm.nih.gov/36757304</a></p></li><li><p>Figus, M, et al., &amp; Rossetti, L (2020). Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study. <i>European journal of clinical pharmacology</i> 76(7) 929–937. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-02863-7&quot;>10.1007/s00228-020-02863-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32285142/&quot;>https://pubmed.ncbi.nlm.nih.gov/32285142</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07CB04;
